Home Cart Sign in  
Chemical Structure| 1707289-21-1 Chemical Structure| 1707289-21-1

Structure of Fisogatinib
CAS No.: 1707289-21-1

Chemical Structure| 1707289-21-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

BLU-554 is a selective inhibitor of FGFR4 with the IC50 of 5 nM.

Synonyms: BLU-554

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Fisogatinib

CAS No. :1707289-21-1
Formula : C24H24Cl2N4O4
M.W : 503.38
SMILES Code : C=CC(N[C@@H]1[C@H](NC2=NC=C3C=C(C4=C(Cl)C(OC)=CC(OC)=C4Cl)C=CC3=N2)COCC1)=O
Synonyms :
BLU-554
MDL No. :MFCD30496704
InChI Key :MGZKYOAQVGSSGC-DLBZAZTESA-N
Pubchem ID :91885617

Safety of Fisogatinib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Fisogatinib

RTK

Isoform Comparison

Biological Activity

Target
  • FGFR4

    FGFR4, IC50:5 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
LX-2 cells 50 ng/mL 24 hours To investigate the effect of FGF19 on the polarization of LX-2 cells towards the iCAF phenotype, results showed that FGF19 promotes iCAF phenotype formation through the activation of the FGFR4-JAK2-STAT3 signaling pathway PMC10460854
Hep3B liver cells 0.72 µM 16 days To test whether Fisogatinib suppresses Hep3B cell proliferation/survival through FGFR4 and to demonstrate that the FGFR4-V550M mutation is a resistance mechanism to Fisogatinib. PMC9729100

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c nude mice Colorectal cancer liver metastasis model Oral Pterostilbene 80 mg/kg, Meropenem 10 mg/kg Three doses at 8-hour intervals To investigate the inhibitory effect of Fisogatinib on FGF19-induced colorectal cancer liver metastasis, results showed that Fisogatinib significantly inhibited liver metastasis and extended the survival of mice PMC10460854

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.99mL

0.40mL

0.20mL

9.93mL

1.99mL

0.99mL

19.87mL

3.97mL

1.99mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories